Efficacy, tolerability, and safety of lanthanum carbonate in hyperphosphatemia: A 6-month, randomized, comparative trial versus calcium carbonate

Nephron - Clinical Practice

Volumn 100, Issue 1, 2005, Pages

  Hutchison, A J ^a   Maes, B ^b   Vanwalleghem, J ^c   Asmus, G ^d   Mohamed, E ^e   Schmieder, R ^f   Backs, W ^g   Jamar, R ^h   Vosskuhler A ⁱ  

^a MANCHESTER ROYAL INFIRMARY   (United Kingdom)

^b UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^c VIRGA JESSE HOSPITAL   (Belgium)

^d KfH Dialysezentrum   (Germany)

^e FREEMAN HOSPITAL   (United Kingdom)

^f UNIVERSITY OF ERLANGEN NUREMBERG   (Germany)

^g ASKLEPIOS HOSPITAL BARMBEK   (Germany)

^h IMELDA HOSPITAL   (Belgium)

ⁱ KfH Dialysezentrum   (Germany)

Author keywords

Calcium carbonate; Hemodialysis; Hypercalcemia; Lanthanum carbonate; Phosphate; Phosphate binders

Indexed keywords

CALCIUM; CALCIUM CARBONATE; LANTHANUM CARBONATE; PARATHYROID HORMONE; PHOSPHATE;

ADULT; ARTICLE; BRONCHITIS; CALCIUM BLOOD LEVEL; CARDIOTOXICITY; CATARACT; CLINICAL TRIAL; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; EUROPE; FEMALE; GASTROINTESTINAL TOXICITY; GRAFT OCCLUSION; HEADACHE; HEMODIALYSIS; HUMAN; HYPERCALCEMIA; HYPERPHOSPHATEMIA; HYPOTENSION; MAJOR CLINICAL STUDY; MALE; METABOLIC DISORDER; MUSCLE CRAMP; NAUSEA; NEUROTOXICITY; PARATHYROID HORMONE BLOOD LEVEL; PHOSPHATE BLOOD LEVEL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RESPIRATORY TRACT DISEASE; RHINITIS; SIDE EFFECT; VOMITING;

ADULT; AGED; AGED, 80 AND OVER; CALCIUM; CALCIUM CARBONATE; FEMALE; HUMANS; LANTHANUM; MALE; MIDDLE AGED; PARATHYROID HORMONE; PHOSPHATES; VITAMIN D;

EID: 18744362733     PISSN: 16602110     EISSN: None     Source Type: Journal    
DOI: 10.1159/000084653     Document Type: Article

References (27)

1. Block GA, Hulbert-Shearon TE, Levin NW, Port FK: Association of serum phosphorus and calcium x phosphate product with mortality risk in chronic hemodialysis patients: A national study. Am J Kidney Dis 1998;31:607-617.
2. Goodman WG: Vascular calcification in chronic renal failure. Lancet 2001;358:1115-1116.
3. Mora Palma FJ, Ellis HA, Cook DB, Dewar JH, Ward MK, Wilkinson R, Kerr DN: Osteomalacia in patients with chronic renal failure before dialysis or transplantation. Q J Med 1983;52:332-348.
4. Nilsson P: Bone disease in renal failure. Clinical and histomorphometric studies. Scand J Urol Nephrol 1984;84:1-68.
5. Drueke TB: Renal osteodystrophy: Management of hyperphosphataemia. Nephrol Dial Transplant 2000;15(suppl 5):32-33.
6. Hernandez P, Johnson CA: Deferoxamine for aluminum toxicity in dialysis patients. ANNA J 1990;17:224-228.
7. Gonzalez-Revalderia J, Casares M, de Paula M, Pascual T, Giner V, Miravalles E: Biochemical and hematological changes in low-level aluminum intoxication. Clin Chem Lab Med 2000;38:221-225.
8. Rob PM, Niederstadt C, Keusche E: Dementia in patients undergoing long-term dialysis: Aetiology, differential diagnoses, epidemiology and management. CNS Drugs 2001;15:691-699.
9. Zacharias JM, Fontaine B, Fine A: Calcium use increases risk of calciphylaxis: A case-control study. Perit Dial Int 1999;19:248-252.
10. Martin KJ, Gonzalez EA: Strategies to minimize bone disease in renal failure. Am J Kidney Dis 2001;38:1430-1436.
11. Hsu CH: Are we mismanaging calcium and phosphate metabolism in renal failure? Am J Kidney Dis 1997;29:641-649.
12. Sherrard DJ, Hercz G, Pei Y, Maloney NA, Greenwood C, Manuel A, Saiphoo C, Fenton SS, Segre GV: The spectrum of bone disease in end-stage renal failure - An evolving disorder. Kidney Int 1993;43:436-442.
13. Chertow GM, Burke SK, Raggi P: Sevelamer attenuates the progression of coronary and aortic calcification in hemodialysis patients. Kidney Int 2002;62:245-252.
14. Chertow GM, Dillon M, Burke SK, Steg M, Bleyer AJ, Garrett BN, Domoto DT, Wilkes BM, Wombolt DG, Slatopolsky E: A randomized trial of sevelamer hydrochloride (RenaGel) with and without supplemental calcium. Strategies for the control of hyperphosphatemia and hyperparathyroidism in hemodialysis patients. Clin Nephrol 1999;51:18-26.
15. Slatopolsky EA, Burke SK, Dillon MA: RenaGel, a non-absorbed calcium- and aluminum-free phosphate binder, lowers serum phosphorus and parathyroid hormone. The RenaGel Study Group. Kidney Int 1999;55:299-307.
16. Goldberg DI, Dillon MA, Slatopolsky EA, Garrett B, Gray JR, Marbury T, Weinberg M, Wombolt D, Burke SK: Effect of RenaGel, a non-absorbed, calcium- and aluminium-free phosphate binder, on serum phosphorus, calcium, and intact parathyroid hormone in end-stage renal disease patients. Nephrol Dial Transplant 1998;13:2303-2310.
17. Indridason OS, Quarles LD: Hyperphosphatemia in end-stage renal disease. Adv Ren Replace Ther 2002;9:184-192.
18. Locatelli F, D'Amico M, Pontoriero G: Lanthanum carbonate. IDrugs 2003;6:688-695.
19. Damment SJP, Greaves P, Downes N: The toxicology of lanthanum carbonate (Fosrenol®), a novel non-aluminum, non-calcium phosphate binder. 36th Annual Meeting of the American Society of Nephrology. San Diego 2003.
20. Damment SJP, Webster I: The pharmacology of lanthanum carbonate (Fosrenol®): A novel non-aluminium, non-calcium phosphate binder. 36th Annual Meeting of the American Society of Nephrology, San Diego 2003.
21. Pennick M, Damment SJP, Gill M: The new non-aluminium, non-calcium phosphate binder, lanthanum carbonate, demonstrates pharmacokinetics favourable for use in a chronic kidney disease population. XLI ERA-EDTA Congress, Lisbon, May 2004.
22. Hutchison AJ, Speake M, Al-Baaj F: Reducing high phosphate levels in patients with chronic renal failure undergoing dialysis: A 4-week, dose-finding, open-label study with lanthanum carbonate. Nephrol Dial Transplant 2004;19:1902-1906.
23. Joy MS, Finn WF: Randomized, double-blind, placebo-controlled, dose-titration, phase III study assessing the efficacy and tolerability of lanthanum carbonate: A new phosphate binder for the treatment of hyperphosphatemia. Am J Kidney Dis 2003;42:96-107.
24. Finn WF, Joy MS, Hladik GA: Results of a randomized dose-ranging, placebo-controlled study of lanthanum carbonate for reduction of serum phosphate in chronic renal failure patients receiving hemodialysis. Clin Nephrol 2004;62:193-201.
25. Grohse PM, Giglio JJ, O'Rourke JA, Giglio TC, Burnett TD: The determination of lanthanum in human plasma using inductively coupled plasma mass spectrometry (ICP-MS). 12th International Symposium on Pharmaceutical and Biomedical Analysis (PBA), Monterey, Calif, 2001.
26. Goodman WG, Goldin J, Kuizon BD, Yoon C, Gales B, Sider D, Wang Y, Chung J, Emerick A, Greaser L, Elashoff RM, Salusky IB: Coronary-artery calcification in young adults with end-stage renal disease who are undergoing dialysis. N Engl J Med 2000;342:1478-1483.
27. 4 product, and parathyroid hormone with cardiac mortality risk in chronic hemodialysis patients. J Am Soc Nephrol 2001;12:2131-2138.